AbbVie/$ABBV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
- Ticker
- $ABBV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 57,000
- Headquarters
- North Chicago, United States
- Website
- www.abbvie.com
AbbVie Metrics
BasicAdvanced
$521B
50.79
$5.81
0.19
$6.83
2.35%
Price and volume
Market cap
$521B
Beta
0.19
52-week high
$302.93
52-week low
$190.75
Average daily volume
5.4M
Dividend rate
$6.83
Financial strength
Current ratio
0.87
Quick ratio
0.563
Long term debt to equity
-16.007
Total debt to equity
-12.039
Dividend payout ratio (TTM)
117.37%
Interest coverage (TTM)
8.21%
Profitability
EBITDA (TTM)
31,708
Gross margin (TTM)
73.72%
Net profit margin (TTM)
15.67%
Operating margin (TTM)
36.46%
Effective tax rate (TTM)
19.24%
Revenue per employee (TTM)
$1,160,000
Management effectiveness
Return on assets (TTM)
10.74%
Return on equity (TTM)
-289.98%
Valuation
Price to earnings (TTM)
50.788
Price to revenue (TTM)
7.905
Price to book
-87.83
Price to tangible book (TTM)
-5.75
Price to free cash flow (TTM)
27.65
Free cash flow yield (TTM)
3.62%
Free cash flow per share (TTM)
10.668
Dividend yield (TTM)
2.32%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
10.68%
Earnings per share change (TTM)
339.80%
3-year revenue growth (CAGR)
6.18%
10-year revenue growth (CAGR)
10.09%
3-year earnings per share growth (CAGR)
16.71%
10-year earnings per share growth (CAGR)
4.61%
3-year dividend per share growth (CAGR)
5.34%
10-year dividend per share growth (CAGR)
11.74%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
Analyst projections of the future price of AbbVie stock.
Bulls say / Bears say
AbbVie’s growth engines are now more than covering Humira’s fall: third-quarter revenue rose 10.3%, with Skyrizi up 22.7% and Rinvoq up 23.9%. The company raised its 2026 adjusted EPS guidance to $13.95–$13.99. (AbbVie)
Neuroscience is adding another strong growth stream: third-quarter revenue rose 19.5%, and AbbVie lifted its full-year segment outlook to $13 billion. That helps broaden growth beyond its leading immunology drugs. (The Motley Fool)
Humira continues to shrink under biosimilar competition, with third-quarter sales down 31.2% to $683 million. That decline remains a headwind even as newer immunology drugs grow. (AbbVie)
Imbruvica faces pressure from both pricing rules and competition: sales fell 26.1% in the third quarter. Continued weakness could weigh on the oncology business if newer products do not grow fast enough to offset it. (The Motley Fool)
Aesthetics remains a weak spot, with third-quarter sales down 1.8% operationally and Juvederm down 11.8%. Lower consumer confidence and softness in dermal fillers could keep this portfolio under pressure. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
Upcoming events
AbbVie News
AllArticlesVideos
Funds containing AbbVie
AllEURUSDGBP
Fund name | Fund size | $ABBV weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €134M | 7.58% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 7.50% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 7.50% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 5.67% |
iShares MSCI World Health Care Sector Advanced€CBUF | $918M | 5.67% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.